PDCD1 and melanoma: Particularly relevant was the improvement in term of PFS and OS associated with pembrolizumab (Keytruda®), a second anti-PD-1 antibody utilized for treatment of advanced melanoma compared to anti-CTLA-4 therapy113,116.